Hologic Inc (NASDAQ:HOLX) Upgraded By Citi

Hologic Inc (NASDAQ:HOLX) stock rose 1.24% (As on April 3, 11:11:40 AM UTC-4, Source: Google Finance) after Citi upgraded the company to Buy from Neutral with a price target of $95, up from $80. The firm believes the company’s fiscal year outlook looks conservative and does not rely on a significant second-half market recovery, differentiating itself from peers. Hologic received a favorable review, with Citi citing the company’s strong core performance. The firm believes that the market has overemphasized the potential impact of the US Preventive Services Task Force (USPSTF) guidelines, which could change. Citi anticipates that any such change would be manageable in Hologic’s forward-year estimates.

Hologic, has raised its annual sales forecast on Thursday, on the back of strong demand for its diagnostics and breast health products. The company manufactures and supplies diagnostics tests and assays, medical imaging systems and surgical products focused on healthcare needs of women. Amid a recovery in surgical procedure volumes, Hologic expects growth in revenue from new business lines, particularly from its ongoing strategic expansion efforts in the breast health segment.

Hologic upgraded its annual sales forecast to between $3.99 billion and $4.07 billion from its prior forecast of $3.92 billion to $4.02 billion. The company, however, expects second-quarter revenue in the range of $990 million-$1.01 billion, compared with analysts’ estimates of $998.09 million, according to LSEG data.

Its breast health segment, which offers solutions in radiology, breast surgery, pathology, recorded a 13% rise in quarterly sales to $377.7 million, above analysts’ estimates of $373.05 million, primarily due to higher capital equipment revenue. Hologic’s revenue for the quarter ended Dec. 30, was $1.01 billion, above analysts’ average estimate of $986.12 million, according to LSEG data.

Its diagnostics segment, which offers viral load tests, molecular diagnostics assays, among other services, reported a 19.9% fall in sales to $447.8 million year-on-year, dragged by lower sales of COVID-19 assays. The segment’s sales, however, beat analysts’ estimates of $414.55 million. Surgical revenue grew 5.3%, or 4.6% in constant currency, primarily driven by strong results from MyoSure, Fluent Fluid Management, and Laparoscopy.

Cash flow from operations remained strong in the first quarter at $220.0 million. In addition, during the current quarter the Company executed a $500 million accelerated share repurchase agreement (ASR), repurchased 2.2 million shares of its stock in open market trades for $150 million, and paid down $250 million of outstanding floating rate debt under its credit agreement.

Copyright © 2024. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. FXDailyReport.com will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.